William Boulware, MD
Internal Medicine · Florence, SCNPI 1518930940
Payments from drug & device makers
Across 225 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$784
- Amgen$393
- AbbVie$239
- Merck$237
- Sumitomo Pharma America, Inc.$219
- Esperion Therapeutics, Inc.$187
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,814100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $784 |
| Amgen | 27 | $393 |
| AbbVie(2 entities) | 18 | $239 |
| Merck | 12 | $237 |
| Sumitomo Pharma America, Inc. | 9 | $219 |
| Esperion Therapeutics, Inc. | 11 | $187 |
| Abbott | 11 | $171 |
| Novartis | 10 | $161 |
| Amarin Pharma, Inc. | 11 | $158 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $144 |
| Pfizer | 9 | $139 |
| Sanofi-aventis U.S. LLC | 7 | $99 |
| Lilly USA, LLC | 6 | $86 |
| GSK | 5 | $83 |
| Johnson & Johnson | 5 | $71 |
| Eisai Inc. | 4 | $56 |
| Exact Sciences | 3 | $52 |
| Boston Scientific | 3 | $51 |
| Aytu Biopharma, Inc. | 3 | $50 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Radius Health, Inc. | 2 | $38 |
| Cvrx, Inc. | 2 | $38 |
| Dexcom, Inc. | 2 | $37 |
| AstraZeneca | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Bayer | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Shield Therapeutics Inc | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$3,814 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 240 | $172,341 |
| JardianceEmpagliflozin | 119 | $86,376 |
| OzempicSemaglutide | 64 | $75,493 |
| RybelsusSemaglutide | 69 | $67,192 |
| XareltoRivaroxaban | 82 | $57,234 |
| EntrestoSacubitril/Valsartan | 38 | $32,425 |
| Wellbutrin XlBupropion Hcl | 12 | $31,127 |
| MyrbetriqMirabegron | 43 | $27,668 |
| LinzessLinaclotide | 34 | $25,976 |
| GlyxambiEmpagliflozin/Linagliptin | 22 | $24,722 |
| JanuviaSitagliptin Phosphate | 26 | $19,964 |
| Testosterone | 33 | $16,259 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 50 | $15,798 |
| TrintellixVortioxetine Hydrobromide | 26 | $15,108 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $14,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lipitor | $139 | $186,811251 claims |
| Novo NordiskOzempic, Rybelsus | $784 | $142,685133 claims |
| Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr, Tradjenta | $14 | $125,633170 claims |
| Johnson & JohnsonXarelto | $71 | $57,23482 claims |
| NovartisEntresto | $161 | $32,42538 claims |
| AbbVieLinzess, Synthroid | $239 | $32,374121 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $27,66843 claims |
| GSKArexvy, Shingrix, Breo Ellipta | $83 | $26,41186 claims |
| Lilly USA, LLCMounjaro, Trulicity | $86 | $26,21427 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $34 | $25,97530 claims |
| MerckJanuvia | $237 | $19,96426 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $19 | $15,10826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Florence
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
- Jerry BackNorth Charleston$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.